Global Partners LP (GLP) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Global Partners LP (GLP)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

49.28

3.02 (6.53%)

At close: Jan 14, 2025, 3:59 PM

49.08

-0.41%

After-hours Jan 14, 2025, 07:00 PM EST

undefined% (undefined)

Bid	48.17
Market Cap	1.68B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	3.31
PE Ratio (ttm)	14.89
Forward PE	n/a
Analyst	Strong Buy

Ask	50
Volume	46,466
Avg. Volume (20D)	77,003
Open	45.89
Previous Close	46.26
Day's Range	45.89 - 49.96
52-Week Range	37.00 - 58.77
Beta	undefined

About GLP

Global Partners LP engages in the purchasing, selling, gathering, blending, storing, and logistics of transporting gasoline and gasoline blendstocks, distillates, residual oil, renewable fuels, crude oil, and propane to wholesalers, retailers, and commercial customers in the New England states, Mid-Atlantic region, and New York. The company is also involved in the transportation of petroleum products and renewable fuels through rail from the mid-...

[Show more]

Industry Oil & Gas Midstream

Sector Energy

IPO Date Sep 29, 2005

Employees 3,485

Stock Exchange NYSE

Ticker Symbol GLP

Website https://www.globalp.com

Analyst Forecast

According to 1 analyst ratings, the average rating for GLP stock is "Strong Buy." The 12-month stock price forecast is $54, which is an increase of 9.58% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Global Partners LP is scheduled to release its earnings on Feb 26, 2025, before market opens.
Analysts project revenue of $5.80B, reflecting a 31.55% YoY growth and earnings per share of 0.9, making a -36.17% decrease YoY.

News

2 days ago · businesswire.com

Global Partners Announces Cash Distribution on Series B Preferred Units

WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (the “Partnership”) today announced that the Board of Directors (the “Board”) of its general partner, Global GP LLC, has declared a quar...

5 days ago · proactiveinvestors.com

Tiziana Life Sciences' foralumab reduces side effects of discontinuing GLP-1 agonists

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that its intranasal anti-CD3 monoclonal antibody, foralumab, has demonstrated the ability to mitigate the side effects associated with the discontinua...

1 week ago · youtube.com

GLP-1 makers could be under pressure in 2025

Jared Holz, Mizuho, joins 'Fast Money' to talk what is next for the obesity drug makers in 2025.

1 week ago · youtube.com

Cramer's Mad Dash: Cornell report on GLP-1s shows decrease in consumption of savory snacks

CNBC's Jim Cramer reports on a study from Cornell and its impact on the stock market.

1 week ago · fool.com

Should You Buy the Dip in Novo Nordisk Stock Right Now?

The biggest talking point in the pharmaceutical industry at the moment revolves around treatments known as glucagon-like peptide-1 (GLP-1) agonists. GLP-1 agonists are used to treat diabetes and chron...

2 weeks ago · youtube.com

Novo Nordisk is 'losing its pep' in GLP-1 race: BMO analyst

Coming off of Novo Nordisk's (NVO) sharp stock decline after its experimental weight-loss shot CagriSema was found to help recipients lose less weight than previously forecasted, BMO Capital Markets c...

3 weeks ago · barrons.com

Novo Nordisk Is Ready to Ramp Up GLP-1 Manufacturing Following $11B Factory Deal

Novo has handed Wolff one of the most complex jobs in all of pharmaceuticals.

3 weeks ago · seekingalpha.com

Viking Therapeutics: Holiday Gift

Viking Therapeutics has seen a significant drop, losing 50% in value since late October, despite positive news and promising GLP-1 drug developments. The biotech's oral GLP-1 candidate VK2735 showed i...

3 weeks ago · businesswire.com

TNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss Drugs

BALTIMORE--(BUSINESS WIRE)---- $TNFA--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNFA” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel oral therapies for au...

3 weeks ago · businesswire.com

Vivani Medical Announces Initiation of First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia

ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative biopharmaceutical company developing novel, ultra long-acting drug implants, today anno...

4 weeks ago · marketbeat.com

Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon

Recent sales of a little-known stock, Madrigal Pharmaceuticals NASDAQ: MDGL, could bode well for Novo Nordisk A/S NYSE: NVO. The pharma industry giant has seen explosive sales growth for its GLP-1 ago...

1 month ago · youtube.com

Structure CEO on the competitive landscape for oral GLP-1 drugs

Raymond Stevens, Structure Therapeutics CEO, joins 'Fast Money' to talk its oral GLP-1 offerings.

1 month ago · businesswire.com

Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the design of its pivotal Phase 3 LUCIDITY clinical trial for avexi...

1 month ago · fool.com

After Crashing 27% in the Past Month, Is Viking Therapeutics Stock a Bargain Buy Right Now?

There's a growing number of companies entering the weight loss space, focusing on GLP-1 drugs which can be game changers for their businesses. And one of them is Viking Therapeutics (VKTX -2.70%), whi...

1 month ago · youtube.com

Fmr. FDA Commissioner on how Trump could impact GLP-1 industry

Dr. Scott Gottlieb joins 'Fast Money' to talk how a Trump administration could impact the GLP-1 drug industry.

1 month ago · youtube.com

Millions more Americans might get access to GLP-1 drugs

A new proposal by the Biden administration would see obesity drugs covered under Medicare and Medicaid. Transcript: Conway Gittens: The Dow and the S&P 500 closed at fresh record highs on Tuesday as i...

1 month ago · youtube.com

Biden administration plans to expand coverage of GLP-1 drugs for Americans with Medicare & Medicaid

CNBC's Bertha Coombs joins 'Squawk on the Street' to report on Biden's administration plan to expand coverage of GLP-1 drugs for Americans with Medicare and Medicaid.

1 month ago · businesswire.com

Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist.

2 months ago · seekingalpha.com

Global Partners LP Common Units (GLP) Q3 2024 Earnings Call Transcript

Global Partners LP Common Units (NYSE:GLP ) Q3 2024 Earnings Conference Call November 8, 2024 10:00 AM ET Company Participants Eric Slifka - President & CEO Gregory Hanson - CFO Mark Romaine - COO Sea...

2 months ago · businesswire.com

Global Partners Reports Third-Quarter 2024 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (“Global” or the “Partnership”) today reported financial results for the third quarter ended September 30, 2024. CEO Commentary “Global'...

Load More News